COVID-19 in Baselland: Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 Specific Antibody Responses

CompletedOBSERVATIONAL
Enrollment

477

Participants

Timeline

Start Date

April 10, 2020

Primary Completion Date

May 30, 2021

Study Completion Date

December 31, 2021

Conditions
COVID-19 Infection
Interventions
DIAGNOSTIC_TEST

blood draw

2x 10ml of blood, one vial to obtain the antibodies and one vial in ethylenediaminetetraacetic acid (EDTA) (or citrate-treated) to obtain peripheral blood mononuclear cells (PBMCs)

DIAGNOSTIC_TEST

fingertip tests for POC assays

performing POC test by taking two blood drops from the fingertip

DIAGNOSTIC_TEST

saliva collection

saliva collection: the patient delivers saliva into an adsorbent filter, which is placed in the Salivette tube, centrifuged at 1,600x g for 15 min at 4°C to remove cells and debris. Native supernatant is used for testing.

DIAGNOSTIC_TEST

collection of swabs

collection of nasopharyngeal and oropharyngeal swabs for PCR testing on the control group (eg negative subpopulation)

Trial Locations (1)

4410

Department of Health, Economics and Health Directorate Canton Basel-Land, Liestal

All Listed Sponsors
collaborator

ETH Zurich (Switzerland)

OTHER

collaborator

Health Department of the Canton of Basel-Stadt

OTHER_GOV

lead

University Hospital, Basel, Switzerland

OTHER

NCT04483908 - COVID-19 in Baselland: Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 Specific Antibody Responses | Biotech Hunter | Biotech Hunter